Solu Therapeutics was established in May 2023 following the granting of an exclusive license to the CyTAC platform from GSK. We are a clinical-stage company advancing our lead program through Phase 1 trials in chronic myelomonocytic leukemia, with additional CyTAC and TicTAC programs rapidly progressing toward development candidate status.
